title: The role of action potential prolongation and altered intracellular calcium handling in the pathogenesis of heart failure.
abstract: Action potential prolongation is a common finding in human heart failure and in animal models of cardiac hypertrophy. The mechanism of action potential prolongation involves altered expression of a variety of depolarising and hyperpolarising currents in the myocardium. In particular, decreased density of the transient outward potassium current seems to play a prominent role, regardless of species, precipitating factors or the severity of hypertrophy. The decreased density of the transient outward current appears to be caused by reduced transcription of Kv4.2 and Kv4.3 and may be caused in part by an inhibitory effect of alpha-adrenoceptor stimulation. During the early stage of the disease process, action potential prolongation may increase the amplitude of the intracellular calcium transient, causing positive inotropy. We argue therefore, that action prolongation may be a compensatory response which may acutely support the compromised cardiac output. In severe hypertrophy and end-stage heart failure however, despite continued action potential prolongation, the amplitude of the calcium transient becomes severely reduced. The mechanism underlying this event appears to involve reduced expression of calcium handling proteins, and these late events may herald the onset of failure. At present the events leading to the late changes in calcium handling are poorly understood. However, chronic activation of compensatory mechanisms including action potential prolongation may trigger these late events. In the present article we outline a hypothesis which describes a potential role for action potential prolongation, and the associated elevation in the levels of intracellular calcium, in maladaptive gene expression and the progression toward cardiac failure.
authors.affiliation: Toronto Hospital, Department of Medicine, Ontario, Canada.
authors.forename: A D
authors.initials: AD
authors.lastname: Wickenden
authors.forename: R
authors.initials: R
authors.lastname: Kaprielian
authors.forename: Z
authors.initials: Z
authors.lastname: Kassiri
authors.forename: J N
authors.initials: JN
authors.lastname: Tsoporis
authors.forename: R
authors.initials: R
authors.lastname: Tsushima
authors.forename: G I
authors.initials: GI
authors.lastname: Fishman
authors.forename: P H
authors.initials: PH
authors.lastname: Backx
mesh_terms: D000200:Action Potentials; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D015220:Calcium Channels / Q000378:metabolism; D006332:Cardiomegaly / Q000378:metabolism; D006333:Heart Failure / Q000209:etiology* / Q000378:metabolism; D006801:Humans; D008955:Models, Cardiovascular; D009206:Myocardium / Q000378:metabolism*; D051672:Shal Potassium Channels
chemical_list: D015220:Calcium Channels; C497018:KCND2 protein, human; D051672:Shal Potassium Channels; D002118:Calcium